Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22386546 | 0.91 | MAPT (0.39) | MAPTEPHX1ANPEPALDH1A1LMNA | |
| SCHEMBL25919983 | 0.86 | EPHX1 (0.36) | EPHX1FOLH1EPHX2 | |
| SCHEMBL25919981 | 0.83 | EPHX1 (0.41) | EPHX1MEN1KMT2AMAPK1EPHX2 | |
| SCHEMBL807923 | 0.79 | EPHX1 (0.41) | EPHX1MEN1KMT2AEPHX2 | |
| SCHEMBL22386550 | 0.79 | EPHX1 (0.41) | EPHX1MEN1KMT2AEPHX2 | |
| SCHEMBL22386545 | 0.78 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL26045235 | 0.76 | TSHR (0.34) | EPHX1 | |
| SCHEMBL26616752 | 0.75 | PAOX (0.36) | — | |
| SCHEMBL20962328 | 0.75 | EPHX1 (0.46) | EPHX1MEN1KMT2AEPHX2 | |
| SCHEMBL20962292 | 0.75 | EPHX1 (0.46) | EPHX1MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2023-08-10 | — | — | US | disclosed |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248836-A1 | Dosage Regimen for a Controlled-Release PTH Compound | PTH1R, CALCA, CALCR | MAPT 1011/4885EPHX1 2663/4885ANPEP 2242/4885 |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | MAPT 3671/4885EPHX1 1814/4885ANPEP 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.